Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery

Metastatic Malignant Neoplasm in the Brain Clinical Trial

Official title:

Pilot Study to Assess Heterogeneity of the Blood Brain Barrier in Patients With CNS Malignancy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03071913
• Other study ID #: MC1671
• Secondary ID: NCI-2017-0029916
• Status: Completed
• Start date: September 20, 2017
• Est. completion date: January 12, 2023

Study information

• Verified date: April 2024
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This pilot research trial studies blood brain barrier differences in patients with brain tumors undergoing surgery. Studying samples of tissue and blood from patients with brain tumors in the laboratory may help doctors to understand how well drugs get into different parts of a brain tumor. This may help them to determine which types of drugs may be best for treating brain tumors.

Description:

PRIMARY OBJECTIVE:

I. To define the heterogeneity of blood brain barrier (BBB) permeability by assessing drug distribution in a population of patients with central nervous system (CNS) malignancy.

SECONDARY OBJECTIVE:

I. Establish correlation of BBB permeability with radiographic appearance for study patients.

CORRELATIVE RESEARCH OBJECTIVE:

I. To utilize tumor samples to investigate mechanisms for BBB heterogeneity.

OUTLINE:

As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: January 12, 2023
• Est. primary completion date: January 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >= 18 years

• Clinical and radiographic evidence suggesting CNS malignancy

• Suspected newly diagnosed, local, or intracranial recurrence of primary brain tumor OR previously untreated or treated brain metastasis

• Willing to undergo a neurosurgical resection of CNS lesion at Mayo Clinic Rochester

• Able to have magnetic resonance imaging (MRI) imaging with gadolinium contrast (e.g. no cardiac pacemaker, defibrillator, renal failure)

• Females of childbearing potential must have a negative pregnancy test done =< 14 days prior to registration

• Provide written informed consent

• Willing to provide tissue and blood samples for research purposes

• Patients having a study-specific surgical planning MRI only: Creatinine (estimated glomerular filtration rate [eGFR] >= 30) (obtained =< 30 days prior to registration)

Exclusion Criteria:

• Vulnerable populations: pregnant women, prisoners, mentally handicapped

• Unable to undergo a biopsy of CNS lesion

• Documented drug allergy to cefazolin or levetiracetam, or other contraindication to use these drugs in the pre-operative setting (e.g., patient is already on another anti-seizure medication which precludes the clinical indication for pre-operative levetiracetam)

• Patients who are unable to swallow tablets if study drug is administered by mouth

• Patients who are at risk for impaired absorption of oral medication if study drug is administered by mouth; Note: This includes but not limited to, refractory vomiting, gastric resection/bypass, and duodenal/jejunal resection

• Pregnant or nursing women; Note: Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects with chemotherapy; there is also a potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with these drugs, so breastfeeding should be discontinued for the duration of the study

Related Conditions & MeSH terms

• Brain Neoplasms
• Central Nervous System Neoplasm
• Central Nervous System Neoplasms
• Metastatic Malignant Neoplasm in the Brain
• Neoplasms
• Nervous System Neoplasms
• Recurrent Brain Neoplasm

Intervention

Procedure:
• Biospecimen Collection
Undergo collection of tissue and blood samples

Other:
• Laboratory Biomarker Analysis
Correlative studies

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood brain barrier permeability as measured by the ratio of drugs in blood and tissue samples taken during surgery	The ratio of cefazolin and levetiracetam (or lorazepam) and gadolinium in blood taken every 20-30 minutes during surgery will be correlated with the tissue samples. Inter- and intra-subject variability over all patients will be estimated, within specific imaging features between patients, and within open biopsy specimens.	At the time of surgery
Secondary	Radiographic appearance at each tissue sample location	The results of the tissue samples will be compared with the radiographic appearance at each tissue sample location. This will be primarily descriptive in nature.	At the time of surgery